[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"hivtb-coinfection\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:hivtb-coinfection":26},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,1,0,[8],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":22,"briefSummary":24,"conditions":25,"keywords":27,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":35,"lastUpdatePostDateStruct":36,"startDateStruct":39,"completionDateStruct":41,"leadSponsor":43,"locationsCount":46},"100341897","phase-2-efficacy-safety-and-pharmacokinetics-of-dtg-with-rif-100341897",false,"NCT03731559","Efficacy, Safety and Pharmacokinetics of DTG with RIF","Efficacy, Safety and Pharmacokinetics of Dolutegravir 50 Mg Once Daily with Food Versus Dolutegravir 50 Mg Twice Daily in HIV\u002FTB Co-infected Patients Receiving Rifampin-based Antituberculosis Therapy","Inclusion Criteria:\n\n1. documented HIV positive\n2. Aged \\>18 years\n3. ARV naïve (previous exposure to ARV for \\\u003C 2 weeks)\n4. Any CD4 cell count\n5. ALT \\\u003C5 times ULN\n6. estimated GFR\\>60 ml\u002Fmin\u002F1.73m2\n7. Hemoglobin \\>7 mg\u002FL\n8. TB is diagnosed and there is a plan to receive stable doses of RIF containing anti-TB therapy for at least another 4 week period after initiation of ART\n9. No other active OI (CDC class C event) except oral candidiasis or disseminated MAC\n10. Body weight \\>40kg\n11. Able to provide written informed consent\n\nExclusion Criteria:\n\n1. Have documented history of HIV treatment failure or HIV mutation to NRTI, NNRTI, and\u002For INIs\n2. Have previously treated for tuberculosis\n3. Currently using immunosuppressive agents.\n4. Currently using any prohibited medications that can affect the pharmacokinetics of the study drug such as phenobarbital, and carbamazepine\n5. Currently using alcohol or illicit substances that may affect the conduct of the trial as per the opinion of the site Principal Investigator\n6. Unlikely to be able to remain in the follow-up period as defined by the protocol\n7. Patients with proven or suspected acute hepatitis. Patients with chronic viral hepatitis are eligible provided ALT, AST \\\u003C 5 x ULN.\n8. Have Karnofsky performance score \\\u003C30%\n9. Have TB meningitis, bone\u002Fjoints (due to prolonged use of anti-TB drug)\n10. Pregnant or breastfeeding","ALL","18 Years",{"count":19,"type":20},200,"ESTIMATED","INTERVENTIONAL",[23],"PHASE2","The overall aim of the project is to evaluate optimal DTG dose for the combined treatment of TB and HIV infections with RIF based anti-TB therapy. This Stage II trial will determine precisely the PK parameters of DTG in combination with RIF regimen in Thai HIV\u002FTB co-infected patients. After the optimal dose of DTG has been found, it will be further tested in a larger Stage III trial to assess its safety, tolerability and efficacy when used with RIF based regimen.",[26],"HIV\u002FTB Coinfection",[28,29,30,31,32,33],"Efficacy","safety","pharmacokinetics","Dolutegravir","HIV\u002FTB co-infected patients","rifampin-based antituberculosis therapy","RECRUITING","2024-09-30",{"date":37,"type":38},"2024-10-02","ACTUAL",{"date":40,"type":38},"2019-06-25",{"date":42,"type":20},"2025-06-30",{"name":44,"class":45},"The HIV Netherlands Australia Thailand Research Collaboration","OTHER",10]